Gerd Kochendoerfer
Chief Operating Officer at NFlection Therapeutics, Inc.
Gerd Kochendoerfer active positions
Companies | Position | Start | End |
---|---|---|---|
NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Chief Operating Officer | 2021-10-17 | - |
Career history of Gerd Kochendoerfer
Former positions of Gerd Kochendoerfer
Companies | Position | Start | End |
---|---|---|---|
FIBROGEN, INC. | Corporate Officer/Principal | 2004-12-31 | 2007-12-31 |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Chief Operating Officer | 2016-12-31 | - |
Gryphon Therapeutics, Inc.
Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Chief Tech/Sci/R&D Officer | - | - |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Chief Tech/Sci/R&D Officer | 2013-12-03 | - |
Corporate Officer/Principal | 2010-12-31 | 2013-12-03 |
Training of Gerd Kochendoerfer
University of California, Berkeley | Doctorate Degree |
Statistics
International
United States | 7 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Chief Operating Officer | 2 |
Sectoral
Health Technology | 6 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
FIBROGEN, INC. | Health Technology |
Private companies | 4 |
---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Gryphon Therapeutics, Inc.
Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Health Technology |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Health Technology |
NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Health Technology |
- Stock Market
- Insiders
- Gerd Kochendoerfer
- Experience